Leprosy—Insufficient Evidence for Monthly Multidrug Therapy—Reply

Victoria J. Shi,Sneha Poondru,Anand Rajpara
DOI: https://doi.org/10.1001/jamadermatol.2024.1339
IF: 11.816
2024-07-18
JAMA Dermatology
Abstract:In Reply We thank Adler et al for their insightful comments regarding our article and the treatment of lepromatous leprosy. As highlighted by these authors, the US National Hansen's Disease Program (NHDP) has traditionally recommended treating multibacillary leprosy with daily rifampin, dapsone, and clofazimine for 24 months.
dermatology
What problem does this paper attempt to address?